Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02224651 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate Safety and Tolerability of Single Ascending Doses of Multiple Formulations of PF-06650833 in Healthy Subjects Under Fasted and Fed Conditions

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT02224651: Completed Phase 1 study, sponsored by Pfizer.

NCT02224651 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02224651, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

This single ascending dose study is the first evaluation of PF-06650833 in humans. The goals are to assess the safety, tolerability and blood levels of ascending doses of multiple formulations of PF-06650833 and to perform a preliminary assessment of the effect of food on exposure, in healthy subjects.

Interventions

  • DRUG Placebo
  • DRUG PF-06650833

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2014-09
Est. Completion 2015-06
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT02224651 record still lists

NCT02224651 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02224651 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02224651 about?

NCT02224651 is a clinical study titled "Study to Evaluate Safety and Tolerability of Single Ascending Doses of Multiple Formulations of PF-06650833 in Healthy Subjects Under Fasted and Fed Conditions". This single ascending dose study is the first evaluation of PF-06650833 in humans. The goals are to assess the safety, tolerability and blood levels of ascending doses of multiple formulations of PF-06650833 and to perform a preliminary assessment of the effect of food on exposure, in healthy subjec...

What is the current status of trial NCT02224651?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-09. Estimated completion is 2015-06.

What interventions are being tested in trial NCT02224651?

The interventions under investigation include: Placebo (DRUG), PF-06650833 (DRUG).

Who is sponsoring clinical trial NCT02224651?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02224651's enrollment target sits among peer trials

40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02224651, the US trial registry maintained by the National Library of Medicine. NCT02224651 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.